Form 4: AngioDynamics Director Lorinda Burgess Receives Annual Stock Compensation
Director Compensation Grant
AngioDynamics Inc. Director Lorinda Burgess was granted 17,675 shares of common stock as part of her regular annual compensation, which vested immediately.
Summary
- Lorinda Burgess, a Director of AngioDynamics Inc. (ANGO), acquired 17,675 shares of common stock on July 16, 2025.
- These shares were granted as restricted stock units, representing regular annual compensation for her service as a director.
- The restricted stock units vested immediately upon grant.
- Following this transaction, Lorinda Burgess beneficially owns 55,257 shares of AngioDynamics common stock.
- An associated Exhibit 24.1 details a Substitute Power of Attorney, effective January 20, 2025, where Stephen A. Trowbridge appointed Lawrence T. Weiss as the new attorney-in-fact for Lorinda Burgess regarding her SEC filings.
Sentiment
Score: 7
Explanation: The document reports a routine, expected compensation grant to a director, which is a positive for director retention and alignment with shareholder interests. There are no negative financial or operational disclosures.
Positives
- The grant of 17,675 shares of common stock to Director Lorinda Burgess represents standard annual compensation, aligning director interests with shareholders.
- The immediate vesting of the restricted stock units provides immediate ownership and liquidity to the director.
Future Outlook
No forward-looking statements or guidance regarding the company's performance or strategy are provided in this Form 4 filing.
Industry Context
This filing details a routine compensation event for a director, which is a common practice across publicly traded companies to align director incentives with shareholder value. It does not provide information on broader industry trends or competitive landscape.
Comparison to Industry Standards
- Director compensation through restricted stock units is a standard practice in the U.S. public company landscape, aligning director interests with long-term shareholder value.
- The specific amount of 17,675 shares would need to be compared to compensation packages for directors at similarly sized medical technology companies to assess its relative scale, but this document does not provide such comparative data.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-Fact for Lorinda Burgess | Stephen A. Trowbridge | Lawrence T. Weiss | 01/20/2025 | Substitution of attorney-in-fact for SEC filing purposes. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Substitute Power of Attorney | Stephen A. Trowbridge, the previous attorney-in-fact for Lorinda Burgess, appointed Lawrence T. Weiss as the new substitute attorney-in-fact. This change is for the purpose of executing and filing Forms 3, 4, and 5 with the SEC on behalf of Lorinda Burgess. | 01/20/2025 | This administrative change ensures continuity and proper legal representation for the director's SEC filing obligations, maintaining compliance with Section 16 of the Securities Exchange Act of 1934. |
Related Party Transactions
- The grant of 17,675 shares of common stock to Director Lorinda Burgess constitutes a related party transaction, as it is compensation provided by the company to a member of its board of directors. This is a standard and disclosed form of related party compensation.
Stakeholder Impact
- Shareholders: The grant represents a minor dilution of existing shares but is a standard cost of corporate governance and director compensation, intended to align director interests with shareholder value.
- Director (Lorinda Burgess): Directly benefits from the compensation in the form of company stock, increasing her ownership stake and aligning her financial interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 01/20/2025 | Effective date of the Substitute Power of Attorney appointing Lawrence T. Weiss as attorney-in-fact for Lorinda Burgess. |
| 07/16/2025 | Date of transaction where Lorinda Burgess acquired 17,675 shares of common stock. |
| 07/18/2025 | Date of signature for the Form 4 filing by Lawrence T. Weiss, Attorney in Fact. |
Keywords
AngioDynamics, ANGO, SEC Form 4, insider transaction, director compensation, restricted stock units, RSU, stock grant, beneficial ownership, corporate governance, power of attorney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.